earnings
confidence high
sentiment positive
materiality 0.65
Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M
Evofem Biosciences, Inc.
2025-Q3 EPS reported
-$0.02
revenue$10,622,000
- Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.
- Net loss attributable to common stockholders $1.7M ($0.01 per share) vs $2.4M ($0.02) prior year.
- Total operating expenses decreased 42% to $4.0M, helped by $1.9M gain from change in Rush royalty estimate.
- Terminated merger with Aditxt after stockholders did not approve the deal at Oct 20 special meeting.
- Advancing manufacturing cost reduction targeting ~50% lower COGS for both PHEXX and SOLOSEC.